Exosome therapy for hair loss: Separating scientific evidence from promotional gimmicks

What are exosomes?

To separate real biological exosomes from crudely filtered cellular debris, we need to define an exosome first. Extracellular vesicles (EVs) are lipid membrane-bound vesicles secreted by eukaryotic cells.^[5] Scientists broadly classify them into three categories based on size and how they are synthesized^[9]:

1. Apoptotic Bodies: Large vesicles (1,000–5,000 nm) released when a cell dies, containing fragmented DNA and cell debris.^[9]

2. Microvesicles: Medium-sized vesicles (100–1,000 nm) that pinch directly off the cell's outer membrane.^[9,10]

3. Exosomes: The smallest vesicles (30–150 nm), originating strictly from deep within the cell's endosomal pathway.^[5,9,10]

Exosomes are not cellular trash. They are highly sophisticated vesicles with an active cargo within them.^[5] Protected by a lipid bilayer made up of cholesterol, sphingomyelin, and ceramides, exosomes carry a complex biological cargo.^[11] They transport specific proteins, cytokines, messenger RNAs (mRNAs), microRNAs (miRNAs), and long non-coding RNAs (lncRNAs). Because their lipid shell protects these fragile nucleic acids from getting destroyed by enzymes outside the cell, exosomes can safely travel through tissue spaces and actively regulate the gene expression of distant target cells.^[10,12]

Biogenesis of exosomes

The clinical efficacy of exosomes depends entirely on their unique biogenesis. Cells produce exosomes through a complex intracellular assembly.^[9] It starts when the plasma membrane folds inward to form an early endosome. As this structure moves deeper into the cytoplasm, it matures into a late endosome, which is later known as a multivesicular body (MVB).^[9,10] The critical step in biogenesis is when the membrane of the MVB buds inward into its own center, creating numerous smaller vesicles called intraluminal vesicles (ILVs). Cells manage this inward budding via two primary pathways:

Mechanism of action in hair regeneration

When we introduce exosomes to the scalp, they must navigate the follicular microenvironment to reach dermal papilla cells (DPCs)—the master regulators of the hair follicle—and outer root sheath cells (ORSCs) [Figure 1].^[13-19]

Close

Figure 1: Flow chart of mechanism of action of exosomes in hair regeneration.

Export to PPT

Sources of exosomes: finding the best for hair loss according to level of evidence

While almost all eukaryotic cells secrete exosomes, their biological cargo—and therefore their clinical use for hair restoration—depends entirely on the parent cell [Table 1].^[5,17]

Exosomes used in studies vs. commercial preparations available to clinicians

A vast, often ignored gap exists between the strict academic research proving that exosomes work and the reality of the commercial products sold to practitioners every day as exosomes.^[2,25]

In the peer-reviewed clinical studies that show amazing results (like measurable increases of up to 35 hairs/cm² and visibly thicker shafts), researchers use highly processed exosomes prepared in advanced laboratory environments.^[18,19,26] These lab-prepared exosomes go through meticulous purification protocols. Teams use differential ultracentrifugation (spinning at speeds exceeding 100,000 x g), tangential flow filtration, or size-exclusion chromatography.^[2,27] These steps ensure the maximum isolation of intact, functional 30-150 nm vesicles, actively separating away the large apoptotic bodies and cellular debris.^[2,27] Those researchers then rely on nanoparticle tracking analysis (NTA) to quantify the exact dosage delivered.^[2,8]

So, the question is, how do companies make the products that are sold commercially? The truth is, the vast majority of commercial products marketed directly to clinics are not only exosomes.^[2,25,28] They are essentially crudely filtered conditioned media (CM) with a variable proportion of exosomes depending upon the GMP followed by the companies.^[28] Commercial manufacturers grow stem cells in large bioreactors. As the cells live and grow, they secrete substances into the nutrient broth (the media). To maximize profit and bypass expensive, time-consuming steps like ultracentrifugation, many manufacturers simply run this broth through a basic filter to remove whole cells, then package the remaining fluid.^[27,28] This conditioned media is a crude extract of cell debris, massive free-floating protein aggregates, metabolic waste, and an unquantifiable mixture of various extracellular vesicles. Because it remains unpurified, the actual concentration of true exosomes is extremely low, while the concentration of inflammatory debris is high.^[2,28] While there are companies that may have stringent regulations for producing exosomes containing products, and may have a decent yield of exosomes in their products, currently, it can be said that no commercial product as of now has pure exosomes.

Bioengineered exosomes: The future of precision trichology

Looking forward, researchers are not just passively harvesting vesicles; they are actively manipulating the exosome cargo. Through advanced techniques like electroporation, scientists temporarily shock the exosome membrane to open it up, loading MSC-derived exosomes with highly specific molecular drugs.^[29] Current ongoing studies load exosomes with specific small interfering RNAs (siRNAs) engineered to directly silence the androgen receptor gene or DKK-1 right inside the dermal papilla.^[30] These bioengineered 'designer exosomes' are currently undergoing trials to establish standardized dosing and preparatory protocols that may bypass the unpredictable batch-to-batch variability of natural exosomes.^[30,31]

The FDA stance and regulatory realities

Because unpurified conditioned media carries severe contamination risks, and because cellular signaling is incredibly complex, regulatory bodies take a firm stance.^[25] The United States Food and Drug Administration (FDA) strictly classifies any human- or animal-derived exosome intended to treat a disease, or any exosome product administered via injection, as a biological drug.^[25] They require an investigational new drug (IND) application and rigorous clinical trials before any product hits the market.

Right now, there are zero FDA-approved exosome products for injection when it comes to hair loss.^[25] In multiple Public Safety Notifications, the FDA has warned practitioners and patients that injecting unapproved commercial biological products can lead to a cascade of severe adverse events, including systemic bacterial infections and granuloma formation.^[25] We also must watch out for 'exosomewashing'—a marketing trick where manufacturers take simple plant extracts or basic peptide serums, stick the label of the word 'Exosomes', and charge premium prices.^[2] Legitimate commercial exosome products intended for aesthetic use remain legally restricted exclusively to topical application, with or without microneedling.^[2,25]

Evaluating commercial products: a clinician’s checklist

Since no commercial product currently available constitutes a '100% pure' exosome formulation due to the realities of biological manufacturing mentioned above, we must be critical of all the products that are being sold to us as exosomes.^[2] When evaluating a commercial exosome product for topical or microneedling application, the authors strongly recommend ignoring the marketing brochures and demanding the scientific documentation.^[2,8] Few of the parameters found relevant by the authors have been mentioned below in Table 2.